Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer Education in the Era of Immediate Results Access.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026
Same author

The Paused Pathway: Teaching Investigative Consent when Cancer Investigation Stalls.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026
Same author

Heat-related illness symptoms among migrant farmworkers: a systematic literature review and meta-analysis.

BMC public health·2026
Same author

Reassurance as Cancer Education after a Benign Investigation.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026
Same author

A field in motion: The parallel evolution of coaching in modern health professions education and elite sports.

Medical education·2026
Same author

EXPANSE Urban Labs: a panel study to deepen understanding of healthy urban living environments.

Environmental research·2026

Related Experiment Video

Updated: May 3, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K

Ranolazine improves diastolic function in spontaneously hypertensive rats.

Sarah Williams1, Marc Pourrier, Donald McAfee

  • 1Department of Anesthesiology, Pharmacology, and Therapeutics, Life Sciences Institute, University of British Columbia, Vancouver, Canada.

American Journal of Physiology. Heart and Circulatory Physiology
|January 28, 2014
PubMed
Summary

Ranolazine effectively treats diastolic dysfunction in spontaneously hypertensive rats by inhibiting the late sodium current. This mechanism reduces calcium overload, promoting better heart relaxation and decreased stiffness.

Keywords:
cardiomyocytediastolic dysfunctionheart functionlate sodium currentranolazine

More Related Videos

Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter
07:53

Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter

Published on: June 16, 2022

3.3K
A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

6.1K

Related Experiment Videos

Last Updated: May 3, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K
Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter
07:53

Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter

Published on: June 16, 2022

3.3K
A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

6.1K

Area of Science:

  • Cardiovascular Physiology
  • Pharmacology
  • Heart Failure Research

Background:

  • Diastolic dysfunction is a precursor to heart failure with preserved ejection fraction, lacking effective treatments.
  • Ranolazine shows potential in mitigating diastolic dysfunction, but its precise mechanisms require elucidation.
  • Spontaneously hypertensive rats (SHRs) exhibit impaired left ventricular relaxation and increased stiffness, modeling diastolic dysfunction.

Purpose of the Study:

  • To ascertain if ranolazine improves diastolic function in SHRs.
  • To identify the underlying mechanisms through which ranolazine exerts its effects.
  • To test the hypothesis that ranolazine inhibits late sodium current, reducing calcium overload and enhancing ventricular relaxation.

Main Methods:

  • Echocardiography and pressure-volume loop analysis were used to assess cardiac function in aged male SHRs and Wistar-Kyoto rats.
  • The effects of ranolazine and vehicle on heart function and response to dobutamine challenge were evaluated.
  • Isolated cardiomyocytes were studied to determine the impact of ranolazine and tetrodotoxin on late sodium current, sarcomere length, and intracellular calcium.

Main Results:

  • Ranolazine treatment reduced the end-diastolic pressure-volume relationship slope and improved diastolic function in SHRs, particularly during dobutamine challenge.
  • Both ranolazine and tetrodotoxin demonstrated enhanced cardiomyocyte relaxation and reduced diastolic myoplasmic free calcium at high-stimulus rates in SHRs.
  • Elevated late sodium current density was observed in SHRs compared to controls.

Conclusions:

  • Ranolazine is effective in ameliorating diastolic dysfunction in the spontaneously hypertensive rat model.
  • The therapeutic effect of ranolazine is partly attributed to the inhibition of the elevated late sodium current in SHRs.
  • This inhibition leads to a reduction in intracellular calcium overload, promoting improved diastolic function.